of validated stably expressed "reference genes" for accurate data normalization. The aim of 23 this study was to identify and validate a set of reference genes suitable for studying gene 24 expression during equine embryo development. The stable expression of 4 carefully selected 25 reference genes and 1 developmentally regulated gene was examined by qPCR in equine 26 morula to expanded blastocyst stage in vivo embryos. SRP14, RPL4 and PGK1 were 27 identified by geNorm analysis as stably expressed reference genes suitable for data 28 normalization. RPL13A expression was less stable and changed significantly during the period 29 of development examined, rendering it unsuitable as a reference gene. As anticipated, CDX2 30 expression increased significantly during embryo development supporting its possible role in 31 trophectoderm specification in the horse. In summary, we demonstrated that evidence-based 32 selection of potential reference genes can reduce the number needed to validate stable 33 expression in an experimental system; this is particularly useful when dealing with tissues that 34 yield small amounts of mRNA. SRP14, RPL4 and PGK1 are stable reference genes suitable 35
Introduction

39
In eutherian mammals, pre-implantation embryo development is a period of dynamic 40 transition, spanning a range of important events that include cell cleavage, embryonic genome 41 activation, cell lineage segregation, blastocyst formation, initial interaction with the 42 endometrium and ultimately implantation. Large fluctuations in the transcriptome occur 43 during this period, as a result of the switch from maternally-produced to embryo-produced6 comparing early equine embryos across different stages of development or for embryos not 123 subjected to prior RNA amplification. Here we demonstrate that using an evidence-based 124 minimalist strategy, we were able to identify stably expressed reference genes suitable as 125 normalization factors for morula to expanded blastocyst stage equine embryos. 126
127
Materials and methods
128
Collection of in vivo embryos 129
Twenty one embryos were recovered 6.5-7 days after ovulation from 16 Dutch Warmblood 130 mares (aged 4-12 years) inseminated with semen from a single fertile stallion as described 131 previously (Rambags et al. 2008 ). Embryos were recovered by non-surgical uterine lavage 132 using 3 x 1 L pre-warmed (37°C) lactated Ringer's solution (LRS; Baxter, Lessines, Belgium) 133 supplemented with 0.5% fetal calf serum (FCS; Greiner Bio-One, Alphen aan den Rijn, 134 Netherlands). Embryos were then 'washed' through 10 wells of LRS to remove any maternal 135 cells or residual FCS. Embryo diameter was measured using an eye-piece micrometer 136 attached to a SZ60 dissecting microscope (Olympus, Zoeterwoude, Netherlands) and embryos 137 were further classified by developmental stage (morula, early blastocyst or expanded 138 blastocyst; Fig. 1 ) and quality grade (1-4) as described by Tremoleda et al. (2003) . Embryos 139 were snap-frozen in liquid nitrogen in 10 µl LRS and stored at -80°C until RNA extraction. 140
All animal procedures were approved by Utrecht University's Animal Experimentation 141
Commission (DEC). 142
143
RNA extraction and cDNA synthesis 144
Total RNA was extracted from whole individual embryos in 600 µl buffer RLT using an 145
AllPrep DNA/RNA/Protein Mini Kit, and subjected to on-column DNase I digestion using an 146
RNase-Free DNase Set (both Qiagen, Venlo, Netherlands) according to the manufacturer's 147 instructions. RNA was eluted in a final volume of 35 µl RNase-free water. Since the amount7 of RNA recovered from individual embryos in preliminary trials was below the detection 149 limit of a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA), all 150 of the RNA from each individual embryo was synthesized into cDNA. +RT samples were 151 synthesized in a 40 µl reaction volume that contained 24 µl embryo RNA, 1x First strand 152 buffer, 5 mM DTT, 0.5 mM dNTPs (Promega, Madison, WI, USA), 600 ng random primers, 153 40 U RNase In (Promega) and 200 U Superscript III reverse transcriptase (all Invitrogen, 154
Breda, Netherlands unless otherwise stated). To test for genomic DNA (gDNA) 155 contamination, -RT samples were made up in a 20 µl reaction volume that contained 8 µl 156 embryo RNA and the same reagent concentrations but without reverse transcriptase. RNA 157 was added to the reaction mixture after an initial denaturation step of 5 min at 70°C followed 158 by 1 min on ice. Thereafter, the reaction was incubated for 5 min at 25°C, 1 h at 50°C and 5 159 min at 80°C. The quality and purity of cDNA from each embryo was verified using 160 conventional PCR and generic actin-family primers (that amplify both cDNA and any 161 contaminating gDNA of β-actin, γ1-actin and a hypothetical mRNA product identified in the 162 NCBI horse genome database; Table 1 ). For the PCR, the total reaction volume was 25 µl 163 containing 1 µl +RT or -RT embryo cDNA, 1x PCR buffer, 2 mM MgCl 2 , 0.2 mM dNTPs 164 (Promega), 0.5 µM forward primer, 0.5 µM reverse primer and 0.625 U HotStarTaq DNA 165 polymerase (all Qiagen unless otherwise stated). PCR cycling conditions consisted of 15 min 166 at 95°C followed by 35 cycles of 30 sec at 94°C, 30 sec at primer-specific annealing 167 temperature (see ACT Table 1 ) and 1 min at 72°C; with a final extension of 10 min at 72°C. 168
Products were visualized on 1% agarose gels. If suitable for PCR amplification and free of 169 gDNA contamination, both +RT and -RT embryo cDNA samples were diluted 10-fold and 170 frozen at -20°C in multiple single-reaction aliquots until required for qPCR analysis. 171
172
Reference gene selection and primer design 173
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In this study, we tested the expression of four potential reference genes, Phosphoglycerate 174 kinase 1 (PGK1), Signal recognition particle 14kDa (SRP14), and ribosomal proteins L4 175 (RPL4) and L13A (RPL13A). PGK1 was ranked among the 3 most stably expressed genes in 176 oocytes and throughout pre-implantation embryo development in the pig (Kuijk et al. 2007 Primers for each gene were optimized and tested for specificity using 10 µl of 100-fold 200 diluted positive control small intestine (for CDX2) or testis cDNA. Optimal annealing 201 temperatures (T A ) were determined by temperature gradients that spanned the primer melting 202 temperature (Tm) ±5°C. The optimal T A for each primer pair gave the highest quantity and 203 purity of PCR product based on the height, and clean single peak, of its melt curve coupled 204
with an early C q score during qPCR (Table 1) . Once optimized, qPCR product from each 205 primer pair was run with a 100 bp DNA ladder (Invitrogen) on a 2% agarose electrophoresis 206 gel and its size was verified using Quantity One v4.3 software (BioRad, Hercules, CA, USA) 207 (Fig. 2 ). Products were also sequenced using their respective forward and reverse primers in 208 separate sequencing reactions with an ABI PRISM BigDye Terminator v3.1 Ready Reaction 209
Cycle Sequencing Kit and an ABI PRISM 3130xl DNA sequencer (both Applied Biosystems, 210
Nieuwerkerk aan den IJssel, Netherlands). Specificity was validated by comparing these 211 sequences with those from the NCBI horse genomic database. Once validated, qPCR products 212 were precipitation-purified and the absolute amount of DNA quantified by Nanodrop 213 spectrophotometer (Nanodrop Technologies), before 5-fold serial dilution in 10 mM Tris-Cl 214 (pH 8.5) to yield 8 different standard solutions ranging from 100 fg to 1.28 ag. Standards 215 were tested in duplicate and the equivalent of 10 µl of 10-, 100-or 500-fold diluted cDNA 216 from each of 3 test embryos was included on the plate to determine if amounts of cDNA from 217 individual embryos could be quantified within the range of the standard curves. 218
219
Quantitative PCR was performed to optimize all primers and standards and to run final 220 embryo plates using an iQ5 Real Time PCR Detection System and iQ5 Optical System 221 Software v2.0 (BioRad). The total reaction volume was 25 µl per well containing 1x iQ 222 SYBR Green Supermix (BioRad), 0.5 µM forward primer and 0.5 µM reverse primer 223 (Ocimum Biosolutions, IJsselstein, Netherlands) and, for final embryo plates, one of each of 224 the following samples in separate reactions: (i) 100 fg-6.4 ag of 5-fold diluted standards(n=7); (ii) 10 µl of 10-fold diluted embryo cDNA (n=21); (iii) 10 µl of 10-fold diluted embryo 226 -RT sample (n=21); or (iv) 10 µl DNase/RNase-free water (Invitrogen) as no-template 227 control. All samples except the -RT, were run in duplicate (technical replicates), with 228 embryos also divided into biological replicates consisting of 5 morulae, 7 early and 9 229 expanded blastocysts. Both frozen-validated and freshly-prepared standards were included in 230 duplicate on each plate. Due to space limitations, -RT samples were run on a separate plate in 231 a subsequent run on the same day using identical standards. PCR cycling conditions consisted 232 of 4.5 min at 95°C followed by 40 cycles of 15 sec at 95°C, 30 sec at optimal T A and 30 sec at 233 72°C during which fluorescence was acquired; followed by a melt-curve protocol that 234 consisted of 1 min at 95°C, 1 min at optimal T A , then 10 sec at optimal T A increasing to 95°C 235 by 0.5°C per cycle during which a second round of fluorescence was acquired. Raw, non-normalized data obtained during qPCR detection was exported from the iQ5 244 software as starting quantities, derived from the standard curve. Relative starting quantities, in 245 which the highest value was set to 1 for each gene, were then calculated and this data was 246 imported into geNorm for analysis. The gene expression stability measure (M) and pair-wise 247 variation (V) for a particular gene compared with all other tested reference genes was 248 calculated as previously described (Vandesompele et al. 2002) . The optimum number of 249 reference genes to use for normalization was achieved when V≤0.15; a limit beyond which 250 inclusion of further less-stable reference genes for normalization is considered unwarranted 251 
Results
264
Embryo collection and sample quality 265
Twenty one grade 1-2 embryos were collected; they consisted of 5 morulae, 7 early and 9 266 expanded blastocysts ranging in diameter from 126-138, 134-196 and 230-680 µm 267 respectively (Fig. 1) . Conventional PCR amplification using generic actin primers ( Table 1 ) 268 confirmed that the cDNA from all embryos was suitable for PCR amplification and was free 269 of gDNA contamination, based on the presence or absence of a product in the +RT and -RT 270 samples respectively (data not shown). 271
272
Primer validation, quantitative PCR efficiency and relative gene expression 273
Intron spanning/intron-exon overlapping mRNA-specific primers were designed for PGK1, 274 SRP14, RPL4, RPL13A and CDX2, and the optimal annealing temperature (T A ) for each 275 primer pair gave rise to a clean single product peak/dissociation temperature during melt 276 curve analysis (Table 1) . PCR products for each primer pair were of the expected size whenvisualized by agarose gel electrophoresis (Fig. 2) and DNA sequencing confirmed that the 278 products were specific to the target genes of interest (data not shown). Amplification was 279 robust on standards ranging from 100 fg-32 ag (and down to 6.4 ag for RPL13A and CDX2) 280 and gave amplification efficiencies of 91. 4 All 5 genes were expressed in all test embryos and the equivalent of 1 µl undiluted or 10-fold 284 diluted embryo cDNA was sufficient to amplify within the working range of the standards for 285 each gene. In the final plates, wells containing primer dimers were excluded from further 286 analysis and expression for all genes was below detectable levels in -RT samples. SRP14 and PGK1 respectively; Fig. 3 ). Pure products were amplified in all embryos; however 292 one duplicate failed to amplify PGK1 in cDNA from 4 embryos (E24, E31, E16 and E17) and 293 one replicate failed to amplify CDX2 in cDNA from 2 embryos (E19 and E16). PGK1 showed 294 the greatest increase in gene expression at the expanded blastocyst stage (368-fold higher) 295 relative to the smallest morula, followed by CDX2 (332-fold higher). RPL13A expression 296 changed the least (117-fold higher) during this period of development. The expression of all 297 genes increased markedly in expanded blastocysts, particularly in those with an embryo 298 diameter >400 µm (E13-E5; Fig. 3) . 299 300
Reference gene expression stability 301
A ranking of the stable expression of each reference gene across the different developmental 302 stages, based on the gene expression stability measure (M), is shown in Table 2 . RPL4 wasthe most stably expressed gene followed by SRP14 and RPL13A, while CDX2 showed the 304 least stable expression. To test whether RPL4 and RPL13A may be co-regulated, we examined 305 whether removal of one from the analysis significantly affected the stability ranking of the 306 other. Exclusion of either of these ribosomal genes resulted in a single-rank decrease in the 307 apparent stability of the remaining gene, although expression of each was still more stable 308 than CDX2 (Table 2 ). These results indicate that the expression patterns of these two genes 309 are so similar that they support each others favourable ranking. Since RPL4 and RPL13A form 310 part of the same ribosomal unit in cells, these results infer that RPL4 and RPL13A may be, at 311 least partially, co-regulated and as such should not be used jointly as normalization factors. 312
313
The pair-wise variation (V) was calculated for the two most stably expressed genes (from 314 each ranking in Table 2 ) when the next most stable genes were included successively, i.e. 315 V2/3, V3/4 and V4/5 (Fig. 4) . We defined the optimal number of genes for normalization as 316 the minimum number sufficient to reduce the pair-wise variation to 0.15, as recommended by 317
Vandesompele et al. (2002) . With all genes included in the analysis, the pair-wise variation of 318 RPL4, SRP14 and RPL13A (V2/3) was already below this threshold (V=0.143), decreased 319
further following the addition of PGK1 (V3/4), but increased after the addition of the least 320 stably expressed developmentally regulated gene, CDX2 (V4/5; Fig. 4a ). Without RPL4, the 321 pair-wise variation of SRP14, PGK1 and RPL13A (V2/3) did not decrease below the threshold 322 (V=0.167) but did increase following the addition of CDX2 (V3/4; Fig. 4b ). However, in the 323 absence of RPL13A, the pair-wise variation of SRP14, RPL4 and PGK1 (V2/3) decreased to 324 the threshold (V=0.151) but increased above this limit after the addition of CDX2 (V3/4; Fig.  325 4c). These results confirm that, in early horse embryos, RPL4 is more stably expressed than 326
RPL13A; as such we recommend the use of RPL4 in combination with SRP14 and PGK1 as 327 suitable reference genes for normalization purposes. 328
Normalized gene expression 330
The relative expression levels of all 5 genes for each embryo were normalized against the 331 chosen reference genes (SRP14, RPL4 and PGK1; Fig. 5 ). Given its putative role in early 332 embryonic development, CDX2 was, not surprisingly, the least stably expressed gene across 333 in vivo equine embryos ranging from 126 µm morulae to 680 µm expanded blastocysts. The 334 ratio of the highest expression of this gene (in embryo E25) to the lowest was 9.8-fold, this 335 compared to 1.8 (E5), 1.8 (E4), 2.0 (E27) and 2.5-fold (E24) differences in expression for 336 SRP14, RPL4, PGK1 and RPL13A respectively (Fig. 5a-e) . Moreover, the overall pattern of 337 CDX2 expression across individual embryos was considerably more variable than for any of 338 the potential reference genes. 339
340
Normalized relative expression for all five genes was also examined in the embryos after 341 grouping by developmental stage (morula, early blastocyst and expanded blastocyst; Fig. 6 ). 342
After grouping, PGK1 appeared the most stably expressed gene, followed by SRP14 and 343 RPL4 with less than 1.1, 1.2 and 1.2-fold difference in expression respectively between the 344 stages ( Fig. 6a-c) . The difference in RPL13A gene expression was over 1.5-fold and 345 decreased significantly between morula and expanded blastocyst stages, again suggesting that 346 this gene is less suitable for use as a normalization factor across these developmental stages in 347 the horse (P=0.007; Fig. 6d ). Expression of CDX2 increased significantly by more than 1.8-348
fold from the morula to expanded blastocyst stage, consistent with a role in trophectoderm 349 specification (P=0.02; Fig. 6e Functionally co-regulated genes can confound geNorm analysis because their pair-wise 387 variation will be smaller across experimental treatments than unrelated genes, leading to an 388 overestimate of expression stability. RPL4 and RPL13A were both included in the current 389 study to determine which was more stably expressed in horse embryos, since they have been 390
shown to exhibit species-specific differences (ranked 2 nd and 4 th in mouse but 12 th and 5 th in 391 man respectively; de Jonge et al. 2007 ). Exclusion of one of these two ribosomal genes from 392 geNorm analysis negatively affected the stability ranking of the other (Table 2) , supporting 393 the hypothesis that these genes are co-regulated and as such should not be used jointly as 394 normalization factors. In this respect, RPL13A was discounted as a reference gene because its 395 expression was less stable than RPL4, and not sufficient to reduce the pair-wise variation of 396 the 3 best reference genes below the recommended threshold (Table 2 and Fig. 4b) . After 397 normalization, RPL13A gene expression was shown to decrease significantly during morula to 398 expanded blastocyst development (Fig. 6d) and, although the magnitude of this change was 399 small (just over 1.5-fold), it does suggest that RPL13A is not stably expressed under these 400 conditions, and its use as a reference gene is thus not recommended. 401
402
CDX2 was included as a 'developmentally regulated' control in this study because it is known 403 to be highly regulated during blastocyst formation in the mouse (Strumpf et al. 2005) . As 404 expected, CDX2 had the lowest stability ranking and greatest negative effect on increasing 405 pair-wise variation among the tested genes (Table 2 and Fig. 4 ). In addition, normalized 406 CDX2 expression was more variable across individual embryos with a nearly 10-fold 407 Li, X., Zhou, S.G., Imreh, M.P., Ahrlund-Richter, L., and Allen, W.R. 
